UBS Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle has maintained a Buy rating on Biomarin Pharmaceutical and raised the price target from $104 to $106.
October 30, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Eliana Merle has maintained a Buy rating on Biomarin Pharmaceutical and increased the price target from $104 to $106, indicating positive expectations for the stock.
The Buy rating and increased price target from UBS suggest a positive outlook for Biomarin Pharmaceutical, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100